Biotech Values

[DewDiligence]

Aha. I manage a family portfolio with a modest ZBH holding, and I was wondering why the stock has been selling off lately, particularly after a bullish 2Q23 earnings report.

I have a large position in ABT, but I don't think ABT will be strongly affected by the uptake of weight-loss drugs. ABT is not a player in the hip- and knee-implant market, ZBH's main business, where obesity clearly plays a major role. Meanwhile, ABT is strong beneficiary of the increasing wolrdwide prevalence of T2D (#msg-172393915).